Saybrook Capital NC Grows Position in Kenvue Inc. (NYSE:KVUE)

Saybrook Capital NC grew its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 8.9% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 352,380 shares of the company's stock after purchasing an additional 28,900 shares during the period. Kenvue makes up about 2.3% of Saybrook Capital NC's portfolio, making the stock its 15th biggest position. Saybrook Capital NC's holdings in Kenvue were worth $8,450,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of KVUE. LaFleur & Godfrey LLC lifted its stake in shares of Kenvue by 29.8% in the 4th quarter. LaFleur & Godfrey LLC now owns 81,300 shares of the company's stock valued at $1,736,000 after purchasing an additional 18,650 shares during the last quarter. Atria Wealth Solutions Inc. lifted its stake in shares of Kenvue by 106.9% in the 4th quarter. Atria Wealth Solutions Inc. now owns 18,257 shares of the company's stock valued at $390,000 after purchasing an additional 9,432 shares during the last quarter. Private Advisor Group LLC lifted its stake in shares of Kenvue by 34.1% in the 4th quarter. Private Advisor Group LLC now owns 50,076 shares of the company's stock valued at $1,069,000 after purchasing an additional 12,729 shares during the last quarter. Ieq Capital LLC lifted its stake in shares of Kenvue by 20.0% during the 4th quarter. Ieq Capital LLC now owns 12,853 shares of the company's stock worth $274,000 after acquiring an additional 2,146 shares during the last quarter. Finally, Sigma Planning Corp increased its holdings in Kenvue by 2.5% during the 4th quarter. Sigma Planning Corp now owns 39,641 shares of the company's stock worth $846,000 after purchasing an additional 955 shares during the period. 97.64% of the stock is owned by institutional investors.

Kenvue Stock Performance

NYSE KVUE traded down $0.23 during trading hours on Friday, reaching $20.89. The stock had a trading volume of 24,148,905 shares, compared to its average volume of 16,266,401. The stock has a fifty day moving average of $22.85 and a 200 day moving average of $22.37. The stock has a market cap of $40.07 billion, a P/E ratio of 37.97, a price-to-earnings-growth ratio of 3.28 and a beta of 0.98. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $25.17. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.60 and a current ratio of 0.86.

Kenvue (NYSE:KVUE - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.24 EPS for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. The firm had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.69 billion. Kenvue had a return on equity of 20.87% and a net margin of 6.90%. Kenvue's revenue for the quarter was down 3.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.28 earnings per share. Sell-side analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th were given a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, May 14th. This represents a $0.82 annualized dividend and a yield of 3.93%. Kenvue's dividend payout ratio is presently 149.09%.

Analyst Upgrades and Downgrades

KVUE has been the subject of several recent research reports. Barclays boosted their price target on Kenvue from $22.00 to $23.00 and gave the stock an "equal weight" rating in a research report on Monday, May 12th. Citigroup reissued a "neutral" rating on shares of Kenvue in a research report on Friday, June 13th. Redburn Atlantic initiated coverage on Kenvue in a research report on Thursday, April 10th. They issued a "neutral" rating and a $23.50 price target for the company. UBS Group boosted their price target on Kenvue from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Friday, May 9th. Finally, Canaccord Genuity Group boosted their price target on Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $25.33.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.